Compare Bristol-Myers Squibb Co (BMY) vs Vanguard Total International Bond Index Fund ETF (BNDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Vanguard Total International Bond Index Fund ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.83 (market cap $129.94B), while Vanguard Total International Bond Index Fund ETF trades at $47.81. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Vanguard Total International Bond Index Fund ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BMY | BNDX | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | — |
52-Week High | $65.89 | $49.91 |
52-Week Low | $42.60 | $47.57 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
BNDX trades at $47.835 with minimal daily movement (+0.09%), showing technical bearish signals from moving averages while oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payouts of $0.11-$0.12. Market sentiment reflects ongoing concerns about Treasury yields and inflation data, with institutional activity showing mixed positioning changes among major holders.
The international bond ETF faces headwinds from rising global yields and inflation pressures, though steady dividend income provides support. Key risks include Federal Reserve policy uncertainty and Middle East geopolitical tensions affecting oil prices. Institutional interest remains active with recent position adjustments, suggesting cautious but engaged professional investor sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Vanguard Total International Bond Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →
